Hemofiltration in sepsis: where do we go from here?

AUTOR(ES)

Kellum , John A

FONTE

BioMed Central

RESUMO

Hemofiltration as an adjunct to therapy for sepsis is now 10 years old. Despite early successes and significant theoretical advantages, the treatment remains experimental. Although feasibility has been established, efficacy has proved to be much more difficult. Clinical as well as technical difficulties remain important considerations to future studies. These issues are discussed and the brief history of hemofiltration in sepsis is reviewed.

Documentos Relacionados

• Preoperative chemotherapy: where do we go from here?
• Audit in general practice: where do we go from here?
• The health care crisis: where do we go from here? The eighth annual Bronfman lecture.
• Impact factor, scimago indexes and the brazilian journal rating sytem: where do we go from here?
• Update on Proteomics in Arabidopsis. Where Do We Go From Here?1